# Watson Pharmaceuticals clinical trials: 30 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 30 trials with Watson Pharmaceuticals as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Watson Pharmaceuticals: 30 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/watson-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 30
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 30, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 17, 2014 | NCT02193139 | Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis | Watson Pharmaceuticals | Phase 2 | Completed | Hyperhidrosis | 195 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02193139) |
| March 13, 2012 | NCT01553123 | Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma | Watson Pharmaceuticals | Phase 3 | Withdrawn | Leiomyomas | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01553123) |
| March 25, 2011 | NCT01323140 | Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems | Watson Pharmaceuticals | Phase 2 | Completed | Hypogonadism | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01323140) |
| July 13, 2010 | NCT01161563 | Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration | Watson Pharmaceuticals | Phase 4 | Completed | Prostate Cancer | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01161563) |
| June 16, 2010 | NCT01144949 | Study of Silodosin to Facilitate Passage of Urinary Stones | Watson Pharmaceuticals | Phase 2 | Completed | Ureteral Calculi, Kidney Stones, Urolithiasis | 239 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01144949) |
| June 9, 2010 | NCT01140217 | Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in Contraception | Watson Pharmaceuticals | Phase 3 | Completed | Contraceptive Usage | 1,659 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01140217) |
| April 15, 2010 | NCT01104246 | Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men | Watson Pharmaceuticals | Phase 1 | Completed | Hypogonadism | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01104246) |
| June 24, 2009 | NCT00926926 | Effects of Oxybutynin Topical Gel on Gastric Emptying | Watson Pharmaceuticals | Phase 1 | Completed | Healthy | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00926926) |
| June 12, 2009 | NCT00919113 | Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome | Watson Pharmaceuticals | Phase 2 | Completed | Interstitial Cystitis, Painful Bladder Syndrome | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00919113) |
| November 19, 2008 | NCT00793819 | A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia | Watson Pharmaceuticals | Phase 2 | Completed | Nocturia, Prostatic Hyperplasia | 215 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00793819) |
| September 15, 2008 | NCT00752141 | Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers | Watson Pharmaceuticals | Phase 1 | Completed | Healthy Volunteers | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00752141) |
| August 25, 2008 | NCT00740779 | Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome. | Watson Pharmaceuticals | Phase 2 | Completed | Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00740779) |
| September 24, 2007 | NCT00534144 | Comparison Between Effects of Two Iron Preparations on Protein in the Urine | Watson Pharmaceuticals | Phase 1 | Completed | Kidney Failure, Chronic, Anemia, Iron-Deficiency | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00534144) |
| September 11, 2007 | NCT00527917 | A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder... | Watson Pharmaceuticals | Phase 2 | Completed | Interstitial Cystitis | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00527917) |
| July 20, 2006 | NCT00354692 | Effect of Two Iron Preparations on Protein in the Urine | Watson Pharmaceuticals | Phase 4 | Completed | Kidney Failure, Chronic, Anemia, Iron-Deficiency | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00354692) |
| July 11, 2006 | NCT00350636 | A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo | Watson Pharmaceuticals | Phase 3 | Completed | Overactive Bladder | 789 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00350636) |
| September 22, 2005 | NCT00224146 | Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder | Watson Pharmaceuticals | Phase 4 | Completed | Overactive Bladder, Urinary Incontinence, Quality of Life | 2,878 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00224146) |
| September 22, 2005 | NCT00224133 | The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months | Watson Pharmaceuticals | Phase 3 | Completed | Benign Prostatic Hyperplasia | 661 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00224133) |
| September 22, 2005 | NCT00224120 | A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo | Watson Pharmaceuticals | Phase 3 | Completed | Benign Prostatic Hyperplasia | 462 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00224120) |
| September 22, 2005 | NCT00224107 | A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo | Watson Pharmaceuticals | Phase 3 | Completed | Benign Prostatic Hyperplasia (BPH) | 461 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00224107) |
| September 22, 2005 | NCT00224094 | A Comparison of Patch vs. Pill Estrogen Therapy on Testosterone Levels and Thyroid Tests in Menopausal Women | Watson Pharmaceuticals | Phase 4 | Completed | Menopause | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00224094) |
| September 22, 2005 | NCT00224081 | DRIVE Trial (Dialysis Patients' Response to Intravenous \[IV\] Iron With Elevated Ferritin) | Watson Pharmaceuticals | Phase 4 | Completed | Anemia, Iron-Deficiency, Kidney Failure, Chronic, Hemodialysis | 134 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00224081) |
| September 22, 2005 | NCT00224068 | Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy | Watson Pharmaceuticals | Phase 4 | Completed | Anemia | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00224068) |
| September 22, 2005 | NCT00224055 | Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients | Watson Pharmaceuticals | Phase 4 | Completed | Anemia, Iron-Deficiency, Kidney Failure, Chronic | 89 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00224055) |
| September 22, 2005 | NCT00224042 | Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents | Watson Pharmaceuticals | Phase 4 | Completed | Anemia, Iron-Deficiency, Kidney Failure, Chronic | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00224042) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 4 |
| Phase 2 | 7 |
| Phase 2/3 | 1 |
| Phase 3 | 6 |
| Phase 4 | 12 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 29 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Anemia | 6 |
| Anemia, Iron-Deficiency | 6 |
| Kidney Failure, Chronic | 5 |
| Prostatic Hyperplasia | 4 |
| Iron Deficiencies | 4 |
| Cystitis, Interstitial | 2 |
| Hypogonadism | 2 |
| Renal Insufficiency, Chronic | 2 |
| Renal Insufficiency | 2 |
| Bronchiolitis Obliterans Syndrome | 2 |
| Urinary Bladder, Overactive | 2 |
| Prostatitis | 1 |
| Leiomyoma | 1 |
| Hyperhidrosis | 1 |
| Ureteral Calculi | 1 |
| Kidney Calculi | 1 |
| Urolithiasis | 1 |
| Renal Colic | 1 |
| Urinary Incontinence | 1 |
| Prostatic Neoplasms | 1 |
| Contraception Behavior | 1 |
| Urinary Incontinence, Urge | 1 |
| Nocturia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Diagnostic imaging centers in the United States](https://specstream.ai/data/businesses/diagnostic-imaging-centers/united-states)
- [Optometrists in the United States](https://specstream.ai/data/businesses/optometrists/united-states)
- [Appliance repair companies in the United States](https://specstream.ai/data/businesses/appliance-repair-companies/united-states)
- [Gastropubs in the United States](https://specstream.ai/data/businesses/gastropubs/united-states)
- [Restaurants in the United States](https://specstream.ai/data/businesses/restaurants/united-states)
